Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,902 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review.
Bellman P, Gonzalez-Lugo JD, Shahzad M, Amin MK, Khalid MF, Suleman N, Ahmed N, Singh AK, Yacoub A, Zhang D, McGuirk JP, Mushtaq MU. Bellman P, et al. Among authors: ahmed n. Front Oncol. 2024 Apr 11;14:1383730. doi: 10.3389/fonc.2024.1383730. eCollection 2024. Front Oncol. 2024. PMID: 38665946 Free PMC article.
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar MK, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson S, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas Bisneto JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade MJ, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Major A, et al. Among authors: ahmed n. Blood Adv. 2023 Aug 22;7(16):4528-4538. doi: 10.1182/bloodadvances.2023010016. Blood Adv. 2023. PMID: 37026796 Free PMC article.
Favorable outcomes following CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation.
Al-Ramahi JS, Shahzad M, Nguyen A, Li K, Amin MK, Ahmed N, Lutfi F, DeJarnette S, Chaudhary SG, Bansal R, Abdelhakim H, Shune L, Abdallah AO, Singh AK, Abhyankar SH, McGuirk JP, Mushtaq MU. Al-Ramahi JS, et al. Among authors: ahmed n. Bone Marrow Transplant. 2024 Jan;59(1):134-137. doi: 10.1038/s41409-023-02125-x. Epub 2023 Oct 13. Bone Marrow Transplant. 2024. PMID: 37833526 No abstract available.
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
Dima D, Rashid A, Davis JA, Shune L, Abdallah AO, Li H, DeJarnette S, Khouri J, Williams L, Hashmi H, Raza S, McGuirk J, Anwer F, Ahmed N. Dima D, et al. Among authors: ahmed n. Br J Haematol. 2024 Apr;204(4):1293-1299. doi: 10.1111/bjh.19302. Epub 2024 Jan 23. Br J Haematol. 2024. PMID: 38263627
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldés A, Stölzel F, Rathje K, Fischer L, Born P, Schäfer L, Albici AM, Schub N, Kfir-Erenfeld S, Assayag M, Asherie N, Wulf GG, Kharboutli S, Müller F, Shune L, Davis JA, Anwer F, Vucinic V, Platzbecker U, Ayuk F, Kröger N, Khouri J, Gurnari C, McGuirk J, Stepensky P, Abdallah AO, Fernández de Larrea C. Gagelmann N, et al. Among authors: ahmed n. J Clin Oncol. 2024 May 10;42(14):1665-1675. doi: 10.1200/JCO.23.02232. Epub 2024 Feb 15. J Clin Oncol. 2024. PMID: 38358946 Free PMC article.
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated myelodysplastic syndrome: A systematic review and meta-analysis.
Shahzad M, Iqbal Q, Tariq E, Ammad-Ud-Din M, Butt A, Mushtaq AH, Ali F, Chaudhary SG, Anwar I, Gonzalez-Lugo JD, Abdelhakim H, Ahmed N, Hematti P, Singh AK, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: ahmed n. Crit Rev Oncol Hematol. 2024 Apr;196:104310. doi: 10.1016/j.critrevonc.2024.104310. Epub 2024 Feb 27. Crit Rev Oncol Hematol. 2024. PMID: 38423375 Free article. Review.
Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience.
McGuirk M, Shahzad M, Amin MK, Khan MA, Bellman P, Mudaranthakam DP, DeJarnette S, Lutfi F, Ahmed N, Bansal R, Abdelhakim H, Gorsline C, Shoemaker DM, Abdallah AO, Shune L, Abhyankar SH, Singh AK, McGuirk JP, Mushtaq MU. McGuirk M, et al. Among authors: ahmed n. Transpl Immunol. 2024 Mar 19;84:102039. doi: 10.1016/j.trim.2024.102039. Online ahead of print. Transpl Immunol. 2024. PMID: 38513813 Free article.
Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review.
Shahzad M, Khalid MF, Amin MK, Ammad-Ud-Din M, Ilyas U, Mushtaq AH, Butt A, Anwar I, Chaudhary SG, Ahmed N, Shune L, Singh AK, Abhyankar SH, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: ahmed n. Hematol Oncol Stem Cell Ther. 2024 Mar 22;17(2):88-94. doi: 10.56875/2589-0646.1118. Hematol Oncol Stem Cell Ther. 2024. PMID: 38560970
TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating versus Referring Physicians.
Atallah R, Ahmed N, Ayoobkhan F, Saif MSI, Logan E, Shrestha A, Anwer F, Mahmoudjafari Z, Mushtaq MU, Hashmi H, Ganguly S, McGuirk J, Shebli A, Abdallah AO, Banerjee R, Alkharabsheh O. Atallah R, et al. Among authors: ahmed n. Transplant Cell Ther. 2024 May 17:S2666-6367(24)00408-1. doi: 10.1016/j.jtct.2024.05.011. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38763416 No abstract available.
3,902 results